Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

University of Sao Paulo

Status

Terminated

Conditions

Treatment Side Effects

Treatments

Drug: Lipid-lowering agents (Artovastatin)

Study type

Interventional

Funder types

Other

Identifiers

NCT03092154

MYO-HCFMUSP-03

Details and patient eligibility

About

The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact of lipid-lowering agents in this population.

Full description

Impact of the lipid lowering agents on patients with dermatomyositis and polymyositis.

Enrollment

24 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

fullfill all criteria of Bohan and Peter (1975)
dyslipidemia
age> 18 years
prednisone ≤ 0.25 mg/kg/day (or ≤ 15mg/ ay) in the last three months
without changing nutritional habits in the last three months, and during the study period
no change of lifestyle in the last three months, and during the study period

Exclusion criteria

Patients with:

disease relapsing
overlapping myositis
neoplasia associated myositis
diabetes mellitus
current and/or chronic infections
patients undergoing major surgery within six months prior to the study
pregnant patients
previous use of lipid-lowering agents in the last 6 months
in the use of cyclosporin, erythromycin, clarithromycin, fibrates, niacin, azole antifungals, cimetidine, diltiazem
active liver disease or persistent elevations of hepatic enzymes, with no apparent cause, exceeding three times the upper limit of normality